ArticleMedicine2026
Global, regional, and national burden of ovarian cancer from 1990 to 2021: Analysis of risk factors and prediction of trends in 2050.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is one of the most lethal gynecological malignancies globally, with significant variations in incidence, prevalence, and outcomes across regions and population subgroups. This study systematically evaluates the global, regional, and national burden of ovarian cancer from 1990 to 2021, utilizing data from the Global Burden of Disease 2021 framework. Trends in incidence, prevalence, mortality, and disability-adjusted life years were analyzed, with an emphasis on their associations with the Socio-Demographic Index (SDI) and other key risk factors. The analysis highlights substantial disparities in ovarian cancer burden, with low- and middle-SDI regions experiencing the highest mortality-to-incidence ratios. In 2021, ovarian cancer accounted for approximately 298,876 new cases globally, with age-standardized incidence rates declining in high-SDI regions but increasing in low-SDI regions. Mortality trends mirrored this pattern, with significant disparities between high- and low-resource settings. The findings underscore the critical influence of age, genetics, and access to early detection and treatment. Forecasts using an ARIMA model indicate a continued rise in the global burden, particularly in regions with limited healthcare resources. This study underscores the urgent need for targeted interventions to improve ovarian cancer outcomes, including enhanced screening, equitable access to treatment, and strategies addressing modifiable risk factors, particularly in underserved regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.